Inventor · disambiguated record
Christiane Neumann
Also filed as: NEUMANN CHRISTIANE
13 granted patents·26 pending applications·56 citations·filing 2013–2024
90Inventor score
Top patents by PatentIndex Score
39 records- 0193US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 0293US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
- 0392US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 0492US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 0592US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 0691US11459404B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2017·Granted Oct 4, 2022·5 cites·1 claims
- 0791US10323099B2Multispecific domain exchanged common variable light chain antibodiesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 18, 2019·13 cites·12 claims
- 0888US2025043028A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 0987US10087250B2Fc-free antibodies comprising two fab-fragments and methods of useROCHE GLYCART AG·Filed 2013·Granted Oct 2, 2018·10 cites·12 claims
- 1087US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1186US2024425616A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 1285US10781257B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·1 cites·34 claims
- 1384US2023340160A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 1484US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1583US2023076791A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 1682US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1781US2022064296A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 1878US2021253703A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 1977US12103982B2T cell activating bispecific antigen binding moleculesHOFFMANN LA ROCHE·Filed 2021·Granted Oct 1, 2024·0 cites·14 claims
- 2077US2021101979A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 2175US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 2266US2020172633A1Common light chains and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2364US12466889B2Anti-HLA-G antibodies and use thereofHOFFMANN LA ROCHE·Filed 2022·Granted Nov 11, 2025·0 cites·91 claims
- 2463US2020299385A1Antibodies binding to human and cynomolgus cd3 epsilonHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2563US2020325224A1Antibodies binding to human and cynomolgus cd3 epsilonHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2662US11639397B2Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of useROCHE GLYCART AG·Filed 2014·Granted May 2, 2023·0 cites·13 claims
- 2762US2018273643A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 2861US2024018240A1Antibodies binding to cd3 and plapHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2961US2024043535A1IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULESHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3061US2023287145A1Protease-activated t cell bispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3160US2020347147A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3259US2022213199A1Anti-HLA-G antibodies and use thereofHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3359US2021070882A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3458US2017253670A1Common light chains and methods of useHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3555US2022010015A1Antibodies binding to cd3HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3655US2017233475A1Antibodies binding to human and cynomolgus cd3 epsilonHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3746US2017198043A1Bispecific antigen binding moleculesROCHE GLYCART AG·Filed 2016·Application pending·0 cites
- 3845US2017174786A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3938US2018282410A1Anti-cd3xrob04 bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christiane Neumann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →